-
Mashup Score: 0FDA Panel Reluctantly Backs Patisiran for ATTR Cardiomyopathy - 8 month(s) ago
Clinical meaningfulness is a different question, however
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 1Pacing‐induced cardiomyopathy after leadless pacemaker implant: It's all about location, location, location - 8 month(s) ago
Click on the article title to read more.
Source: onlinelibrary.wiley.comCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Please see accompanying editorial: When it comes to risk of #cardiomyopathy after #leadless #PPM, location matters! @DPipilasMD, @shaan_khurshid, @MGHHeartHealth https://t.co/dKtuiLE2eJ
-
-
Mashup Score: 0Dr Milind Desai Highlights New Findings From VALOR-HCM Trial - 8 month(s) ago
After 16 weeks on placebo, patients in the control group were invited to start mavacamten alongside the treatment group, explained Milind Desai, MD, MBA, director of the Hypertrophic Cardiomyopathy Center and vice chair of education at the Heart, Vascular & Thoracic Institute, Cleveland Clinic.
Source: www.ajmc.comCategories: General Medicine Journals and Societies, Latest HeadlinesTweet-
In this @AJMC_Journal interview, Dr Milind Desai at the @ClevelandClinic discusses highlights from the VALOR-HCM trial in patients with advanced symptoms of hypertrophic obstructive #cardiomyopathy (#HCM). Watch here: https://t.co/VTEHZrMTGE https://t.co/fSxgzfXRsh
-
-
Mashup Score: 15A Novel ECG-Based Deep Learning Algorithm to Predict Cardiomyopathy in Patients With Premature Ventricular Complexes: - 8 month(s) ago
Abstract Background Premature ventricular complexes (PVCs) are prevalent and, although often benign, they may lead to PVC-induced cardiomyopathy. We created a deep-learning algorithm to predict lef…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet-
Machine Learning applied to the 12-lead #ECG can predict which patients with PVCs will develop a #cardiomyopathy! https://t.co/ronVyknnm1 #cardiotwitter #epeeps #JACCCEP #DeepLearning #MachineLearning #HRS2023 @jskoruth @VivekReddyMD https://t.co/oHqOswfpuV
-
-
Mashup Score: 0
A trio of studies and new guidelines presented at the ESC Congress 2023 highlight advancement in the management of hypertrophic cardiomyopathy, particularly with use of mavacamten.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet-
At #ESCCongress2023, the spotlight was on mavacamten and its role in obstructive hypertrophic cardiomyopathy. Learn more: https://t.co/DV3vmPAzK5 #Cardiomyopathy
-
-
Mashup Score: 0
A trio of studies and new guidelines presented at the ESC Congress 2023 highlight advancement in the management of hypertrophic cardiomyopathy, particularly with use of mavacamten.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet-
Hear from @DesaiMilindY on the inclusion of mavacamten in new ESC #cardiomyopathy guidelines: https://t.co/ykHOtqPDQU #ESCCongress2023 https://t.co/OvBqrSsU3R
-
-
Mashup Score: 0
A trio of studies and new guidelines presented at the ESC Congress 2023 highlight advancement in the management of hypertrophic cardiomyopathy, particularly with use of mavacamten.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet-
A trio of studies and new guidelines presented at the #ESCCongress2023 highlight advancement in the management of hypertrophic cardiomyopathy, particularly with use of mavacamten. https://t.co/1eJT4XThKI #Cardiomyopathy
-
-
Mashup Score: 0Mavacamten Use Can Reduce Need for Septal Reduction Therapy in oHCM - 8 month(s) ago
Results of the 56-week VALOR-HCM trial provide new insight into the effects of mavacamten in patients with highly symptomatic obstructive hypertrophic cardiomyopathy referred for septal reduction therapy.
Source: www.hcplive.comCategories: General Medicine News, Latest HeadlinesTweet-
Results of the 56-week VALOR-HCM trial provide new insight into the effects of mavacamten (Camzyos; @bmsnews) in patients with symptomatic obstructive HCM referred for septal reduction therapy: https://t.co/gmQzWtZCB7 #Cardiomyopathy https://t.co/vTXjPjlTsi
-
-
Mashup Score: 4Trial demonstrates potential of acoramidis for transthyretin amyloid cardiomyopathy - 8 month(s) ago
Your access to the latest cardiovascular news, science, tools and resources.
Source: www.escardio.orgCategories: Cardiology News and Journals, Latest HeadlinesTweet-
Trial demonstrates potential of acoramidis for transthyretin amyloid #cardiomyopathy https://t.co/bBik3JldQ0 #ESCCongress @JugilSci https://t.co/hmq2W9gojQ
-
-
Mashup Score: 21
Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approach for
Source: OUP AcademicCategories: Cardiologists1, Latest HeadlinesTweet-
RT @ehj_ed: New ESC Guidelines for the management of cardiomyopathies are out. https://t.co/7YRSDfWBlq #cardiomyopathy #HF #cardiotwitter @…
-
2023 ESC Guidelines for the management of cardiomyopathies https://t.co/pomUM0AGdG @arbelo_e
-
"Light wind for benefit and no wind for risk." -- @EdKasper3, of @HopkinsMedicine, weighing the benefit-risk calculus on #patisiran (#Onpattro) for transthyretin amyloid #cardiomyopathy during an FDA advisory meeting. @MedPageCardio https://t.co/twhISGs8Vu